Trials / Completed
CompletedNCT03427502
Anterior Ethmoidal Nerve Block in Prevention of Postoperative Agitation
Anterior Ethmoidal Nerve Block in Prevention of Postoperative Agitation Following Nasal Surgeries With Nasal Packs Under General Anesthesia: A Double Blind Randomized Control Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Lumbini Medical College · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Postoperative agitation is an important complication of general anesthesia, moreover, it has been found with high incidence in ear, nose, throat (ENT) surgeries. We aim to study whether anterior ethmoidal nerve block will be successful in reducing postoperative agitation in those patients. Study population will be randomized into two groups, treatment and control group. Anterior ethmoidal nerve block will be done in treatment group and postoperative agitation compared between these two groups. Agitation score will be scored with Riker Sedation-Agitation Scale (SAS). Ho: Occurrence of post-operative agitation in patients undergoing nasal surgery with nasal pack under general anesthesia is equal in those with ethmoidal nerve block as compared to those without the block. Ha: Occurrence of post-operative agitation in patients undergoing nasal surgery with nasal pack under general anesthesia is not equal in those with ethmoidal nerve block as compared to those without the block.
Conditions
- Postoperative Agitation: Impaired Awareness, Abnormal Cognitive Function, Confusion, and Verbal and Physical Agitation During Recovery From General Anesthesia
- Deviated Nasal Septum
- Chronic Rhinosinusitis (Diagnosis)
- Nasal Polyps
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bupivacaine-epinephrine | 10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline |
| DRUG | normal saline | normal saline |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2019-12-30
- Completion
- 2020-02-28
- First posted
- 2018-02-09
- Last updated
- 2020-09-11
Locations
1 site across 1 country: Nepal
Source: ClinicalTrials.gov record NCT03427502. Inclusion in this directory is not an endorsement.